RejuvenAir® System Trial for COPD With Chronic Bronchitis

Inclusion Criteria * Males and females ≥40 to ≤80 years of age * Subject is able to read, understand, and sign a written Informed Consent in order to participate in the Study * Subject has a diagnosis of chronic bronchitis (CB) and/or chronic obstructive pulmonary disease (COPD) for a minimum of two years. (Chronic Bronchitis is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded) * Subject is classified as having a moderate or severe (GOLD 2/3) airflow obstruction defined by a post-bronchodilator of ≥30% FEV1 to \<80% predicted with a baseline FEV1/FVC of \<0.70 * Subject has a Baseline SGRQ of ≥50 * Subject demonstrates daily cough and significant mucus. * Subject is being treated according to current medically accepted treatment guidelines for chronic bronchitis for minimum of 3 months prior to enrollment into the study. Subject agrees to continue maintenance pulmonary/COPD medications (GOLD standard medications recommended) for the duration of the study * Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study * Subject is able to adhere to and undergo 2 bronchoscopic procedures (cross over subjects may undergo two additional bronchoscopic procedures, if they agree to treatment), per hospital guidelines * Subject demonstrates ability and willingness to use a daily eDiary Exclusion Criteria * Subject has had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 4 weeks prior of initially planned study bronchoscopy * Current diagnosis of Asthma * Subject has Alpha-1 antitrypsin deficiency as defined by blood level \<59 mg/dL * Subject has other origins of respiratory disease aside from chronic bronchitis and COPD * Subject is using e-cigarettes, vaping or taking any inhaled substances not prescribed by a physician * Subject has untreatable or life threatening arrhythmias, inability to adequately oxygenate during the bronchoscopy, or has acute respiratory failure * Subject has bullous emphysema characterized as large bullae \>30 millimeters on HRCT; or subject has stenosis in the tracheobronchial system, tracheobronchomegaly, trachea-bronchomalacia, amyloidosis or cystic fibrosis * Subject has clinically significant bronchiectasis * Subject has had a solid transplant procedure * Subject has a known mucosal tear, has undergone prior lung surgery such as pneumonectomy, lobectomy, bullectomy, or lung volume reduction surgery * Subject has had a prior lung device procedure, including emphysema stent(s) implanted, lung coils, valves, lung denervation, bronchial thermoplasty, cryotherapy or other therapies * Subject is unable to temporarily discontinue use of anticoagulant therapy: warfarin, Coumadin, LMWH, heparin, clopidrogel (or equal) * Subject has a serious medical condition, such as: uncontrolled coagulopathy or bleeding disorder, congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, uncontrolled hypertension or uncontrolled gastric reflux * Subject is pregnant, nursing, or planning to get pregnant during study duration * Subject has or is receiving chemotherapy or active radiation therapy within the past 6 months or is expected to receive chemotherapy during participation in this study * Subject is or has been in another treatment study within 6 weeks of enrollment and agrees to not participate in any other treatment studies for the duration of study participation * Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines)